Drug intelligence / Profile preview

KD1904

Development stage: Preclinical
Lead developer: Kyungdong Pharmaceutical
Modality: Small Molecules

Overview

KD1904 is a small molecule drug candidate being developed by Kyung Dong Pharma for the treatment of Hepatitis B. It is categorized as an Incrementally Modified Drug (IMD), a regulatory classification in South Korea for products that offer improvements in safety, efficacy, or convenience over existing therapies through modifications in composition, dosage form, or formulation. As of early 2021, the candidate was in the preclinical stage of development. Specific details regarding its molecular target or the nature of its incremental modification have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on KD1904.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KD1904.

Explore the full profile